Epidrug Modulated Expression of MiR­-152 and MiR-148a Reverse Cisplatin Resistance in Ovarian Cancer Cells: An Experimental In-vitro Study

Cisplatin is a common agent which is used to treat Epithelial Ovarian Cancer (EOC), but cisplatin resistance is a major obstacle in successful treatment of ovarian cancer. Aberration in epigenetic changes play an important role in disregulation of gene expression. MiR-152 and miR-148a are frequently...

Descripción completa

Detalles Bibliográficos
Autores principales: Khajehnoori, Sahel, Zarei, Fatemeh, Mazaheri, Mahta, Dehghani-Firoozabadi, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shaheed Beheshti University of Medical Sciences 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757992/
https://www.ncbi.nlm.nih.gov/pubmed/33680048
http://dx.doi.org/10.22037/ijpr.2020.15450.13217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757992/
https://www.ncbi.nlm.nih.gov/pubmed/33680048
http://dx.doi.org/10.22037/ijpr.2020.15450.13217

Ejemplares similares